Cellectar Biosciences
CLRB
19 hedge funds and large institutions have $813K invested in Cellectar Biosciences in 2026 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.85% less ownership
Funds ownership: 8.18% → 7.33% (-0.85%)
5% less funds holding
Funds holding: 20 → 19 (-1)
22% less capital invested
Capital invested by funds: $1.04M → $813K (-$230K)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$77.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$22.7K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$32 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$133K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$36.1K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$36K |
| 4 |
SFA
Sequoia Financial Advisors
Akron,
Ohio
|
-$21K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.36K |
CLRB Hedge Fund Activity: Q1 2026 in Review
19 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q1 2026, worth a combined $813K — down 22% from $1.04M a quarter earlier.
Fund positioning in CLRB was balanced in Q1 2026: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $77.9K. The largest seller was DRW Securities, exiting entirely with an estimated $133K sold.
- 19 institutional investors held Cellectar Biosciences (CLRB) as of Q1 2026, down from 20 in Q4 2025.
- Funds reported $813K of Cellectar Biosciences stock for Q1 2026, down 22% quarter-over-quarter.
- 4 funds opened new Cellectar Biosciences positions in Q1 2026 and 4 closed out, a net change of 0 holders.
- The largest Cellectar Biosciences buyer in Q1 2026 was Geode Capital Management, an estimated $77.9K added.
- The largest Cellectar Biosciences seller in Q1 2026 was DRW Securities, an estimated $133K sold.
Based on aggregated 13F filings for Q1 2026.